EUVIMEDEUVIMED entdecken
Crossref

Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic Impact

Luca Monzo iD, Jan Kovar, Barry A Borlaug, Jan Benes, Martin Kotrc, Katerina Kroupova, Antonin Jabor, Janka Franekova, Vojtech Melenovsky

European Journal of Heart Failure · 01.09.2024 · 26 (9) · 1931-1940

DOI: 10.1002/ejhf.3324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 10.06.2024. Verfasst von Luca Monzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Hauptthemen laut MEDLINE: Heart Failure, 3-Hydroxybutyric Acid, Stroke Volume, Biomarkers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Ministry of Health of the Czech Republic, Institute for Clinical and Experimental Medicine - IKEM, National Institute for Research of Metabolic and Cardiovascular Diseases of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with heart failure (HF) display metabolic alterations, including heightened ketogenesis, resulting in increased beta-hydroxybutyrate (β-OHB) formation. We aimed to investigate the determinants and prognostic impact of circulating β-OHB levels in patients with advanced HF and reduced ejection fraction (HFrEF). Methods and results A total of 867 patients with advanced HFrEF (age 57 ± 11 years, 83% male, 45% diabetic, 60% New York Heart Association class III), underwent clinical and echocardiographic examination, circulating metabolite assessment, and right heart catheterization (n = 383). The median β-OHB level was 64 (interquartile range [IQR] 33–161) μmol/L (normal 0–74 μmol/L). β-OHB levels correlated with increased markers of lipolysis (free fatty acids [FFA]), higher natriuretic peptides, worse pulmonary haemodynamics, and lower humoral regulators of ketogenesis (insulin/glucagon ratio). During a median follow-up of 1126 (IQR 410–1781) days, there were 512 composite events, including 324 deaths, 81 left ventricular assist device implantations and 107 urgent cardiac transplantations. In univariable Cox regression, increased β-OHB levels (T3 vs. T1: hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.13–1.72, p = 0.002) and elevated FFA levels (T3 vs. T1: HR 1.39, 95% CI 1.09–1.79, p = 0.008) were both predictors of a worse prognosis. In multivariable Cox analysis evaluating the simultaneous associations of FFA and β-OHB levels with outcomes, only FFA levels remained significantly associated with adverse outcomes.

Conclusions

In patients with advanced HFrEF, increased plasma β-OHB correlate with FFA levels, worse right ventricular function, greater neurohormonal activation and other markers of HF severity. The association between plasma β-OHB and adverse outcomes is eliminated after accounting for FFA levels, suggesting that increased β-OHB is a consequence reflecting heightened lipolytic state, rather than a cause of worsening HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Failure3-Hydroxybutyric AcidStroke VolumeBiomarkersHumansMaleFemaleMiddle AgedPrognosisAgedEchocardiographyHeart TransplantationCardiac Catheterization

Stichwörter der Autor:innen

Beta‐hydroxybutyrateCardiovascular diseaseFree fatty acidHeart failureKetone bodiesPrognosis

Substanzen

3-Hydroxybutyric AcidBiomarkers

Autor:innen und Institutionen

  • Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
  • Université de Lorraine, Centre d'Investigations Cliniques Plurithématique 1433 and Inserm U1116, CHRU Nancy, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
  • Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Luca Monzo

Förderung

  • Ministry of Health of the Czech Republic
  • Institute for Clinical and Experimental Medicine - IKEM
  • National Institute for Research of Metabolic and Cardiovascular Diseases of the Czech Republic
  • European Union - Next Generation EU
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Monzo, L., Kovar, J., Borlaug, B. A., Benes, J., Kotrc, M., Kroupova, K., Jabor, A., Franekova, J., & Melenovsky, V. (2024). Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic Impact. European Journal of Heart Failure, 26(9), 1931-1940. https://doi.org/10.1002/ejhf.3324

Vancouver

Monzo L, Kovar J, Borlaug BA, Benes J, Kotrc M, Kroupova K, et al. Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic Impact. European Journal of Heart Failure. 2024;26(9):1931-1940. doi:10.1002/ejhf.3324

BibTeX
@article{Monzo2024,
  author = {Monzo, Luca and Kovar, Jan and Borlaug, Barry A and Benes, Jan and Kotrc, Martin and Kroupova, Katerina and Jabor, Antonin and Franekova, Janka and Melenovsky, Vojtech},
  title = {Circulating Beta-Hydroxybutyrate Levels in Advanced Heart Failure with Reduced Ejection Fraction: Determinants and Prognostic Impact},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {1931--1940},
  doi = {10.1002/ejhf.3324}
}
Kostenlos starten →